Electrocore LLC
$ 6.55
4.22%
14 Apr - close price
- Market Cap 52,947,000 USD
- Current Price $ 6.55
- High / Low $ 6.76 / 6.28
- Stock P/E N/A
- Book Value -0.21
- EPS -1.65
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -4.79 %
- 52 Week High 8.64
- 52 Week Low 4.16
About
electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.
Analyst Target Price
$19.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-20 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-03-11 | 2024-11-13 | 2024-08-07 | 2024-05-08 | 2024-03-13 | 2023-11-08 | 2023-08-09 | 2023-05-03 |
| Reported EPS | -0.34 | -0.4 | -0.44 | -0.47 | -0.4 | -0.31 | -0.38 | -0.52 | -0.61 | -0.68 | -1.03 | -1.24 |
| Estimated EPS | -0.3925 | 0.07 | -0.15 | -0.4467 | -0.3 | -0.33 | -0.44 | -0.62 | -0.61 | -0.7 | -0.96 | -1 |
| Surprise | 0.0525 | -0.47 | -0.29 | -0.0233 | -0.1 | 0.02 | 0.06 | 0.1 | 0 | 0.02 | -0.07 | -0.24 |
| Surprise Percentage | 13.3758% | -671.4286% | -193.3333% | -5.216% | -33.3333% | 6.0606% | 13.6364% | 16.129% | 0% | 2.8571% | -7.2917% | -24% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.58 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ECOR
2026-04-14 19:39:41
electroCore's Chief Operating Officer, Michael Fox, has filed an initial Form 3 statement with the SEC, establishing him as a reporting person for the company. This filing indicates beneficial ownership but does not report any actual stock transactions or specific holdings in ECOR. Form 3 is required for company insiders to declare their initial beneficial ownership of securities.
2026-04-14 19:39:41
Former electroCore officer Daniel S. Goldberger sold 16,072 shares of common stock for $6.02 per share, totaling approximately $97,000. This sale was primarily to cover tax withholding obligations associated with the vesting of previously issued Restricted Stock Units (RSUs) and was not a discretionary portfolio move. After the transaction, Goldberger still directly holds 291,471 shares of electroCore common stock.
2026-04-14 19:39:41
electroCore, Inc.'s Chief Operating Officer, Michael Fox, was granted an equity award of 70,000 shares of common stock in the form of restricted stock units (RSUs). These RSUs, valued at $0.00 per share at the time of the grant, will vest over three years, with one-third vesting on the first anniversary and the remainder in equal annual installments over the subsequent two years, provided continuous service. Following this grant, Fox directly holds 70,000 shares.
2026-04-10 15:08:58
electroCore (ECOR) saw a 7.1% surge in its stock price, closing at $6.65, driven by optimism regarding its product pipeline, particularly a clinical trial for its nVNS device in PTSD treatment. Despite this rise and an anticipated 33.1% revenue increase, the company faces a projected quarterly loss and recent downward revisions in earnings estimates. Investors are advised to monitor ECOR closely, as its Zacks Rank #3 (Hold) suggests caution amidst conflicting signals.
2026-04-10 01:40:00
electroCore (ECOR) experienced a 7.1% stock surge, closing at $6.65, driven by investor optimism over advancements in its non-invasive vagus nerve stimulation (nVNS) technology, particularly its expansion into PTSD treatment. The company anticipates reporting a quarterly loss of $0.59 per share but expects a 33.1% increase in revenue. Despite a recent boost, a 10.1% downward revision in EPS consensus estimates over the past month suggests investors should monitor the stock closely, as such revisions typically don't lead to sustained gains.
2026-04-08 12:09:48
electroCore, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Joshua Lev, Interim President and CFO, will present at 2:15 pm ET and hold one-on-one meetings. The company, a bioelectronic medicine and wellness firm, focuses on innovative non-invasive bioelectronic technologies for pain management and general wellness.
